Rational Design of HER2-Targeted Combination Therapies to Reverse Drug Resistance in Fibroblast-Protected HER2+ Breast Cancer Cells
Authors
- Ioannis K. Zervantonakis (ORCID: https://orcid.org/0000-0003-2386-9553)
- Matthew D. Poskus (ORCID: https://orcid.org/0000-0003-3633-0987)
- Ruxuan Li (ORCID: https://orcid.org/0000-0002-3619-368X)
- Jacob D. McDonald
- Kyle Norcoss
- Matthew Laird
Institutions
- University of Pittsburgh (US)
- UPMC Hillman Cancer Center (US)
- McGowan Institute for Regenerative Medicine (US)
Publication Details
- Journal
- Cellular and Molecular Bioengineering
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1007/s12195-024-00823-0
- Citations
- 1
- Primary Topic
- HER2/EGFR in Cancer Research
- Type
- article
- Field-Weighted Citation Impact
- 0.28
Funders
- National Cancer Institute
- National Institute of Biomedical Imaging and Bioengineering